Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 619-627
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.619
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.619
Table 1 Charlson Co-morbidity index
Co-morbid condition | cCCI weights | uCCI weights |
Myocardial infarction | 1 | 0 |
Congestive heart failure | 1 | 2 |
Peripheral vascular disease | 1 | 0 |
Cerebrovascular disease | 1 | 0 |
Dementia | 1 | 2 |
Chronic obstructive pulmonary disease | 1 | 1 |
Connective tissue disorder | 1 | 1 |
Peptic ulcer disease | 1 | 0 |
Mild liver disease | 1 | 2 |
Diabetes without complication | 1 | 0 |
Diabetes with complication | 2 | 1 |
Hemiplegia or paraplegia | 2 | 2 |
Chronic kidney disease stage III | 2 | 1 |
Any malignancy without metastasis | 2 | 2 |
Leukemia | 2 | |
Lymphoma | 2 | |
Moderate or severe liver disease | 3 | 4 |
Metastatic tumor | 6 | 6 |
AIDS | 6 | 4 |
Maximum score | 33 | 24 |
Table 2 Demographic and baseline characteristics of the study population
Variable | Study population (n = 130) |
Age, yr, median (IQR) | 62 (48, 73) |
Females | 59 (45.4) |
Body mass index, kg/m2, median (IQR) | 28.7 (26, 36) |
Smoking | 38 (29.2) |
Alcohol | 30 (23.1) |
Diarrhea | 34 (26.2) |
Nausea | 32 (24.6) |
Abdominal pain | 21 (16.2) |
Anorexia | 34 (26.2) |
Other gastro-intestinal symptoms1 | 37 (28.5) |
X-ray findings2 | 87 (66.9) |
Hypertension | 69 (53.1) |
Admitted to ICU | 58 (44.6) |
On ventilator | 43 (33.1) |
Age-adjusted Charlson Index, median (IQR) | 3.5 (1, 6) |
On medications with gastro-intestinal side-effects | 46 (35.4) |
Death | 28 (21.5) |
Lactic Acid, mean (SD), n = 97 | 1.7 (1.4) |
Lactic acid dehydrogenase, mean (SD), n = 92 | 424 (182.6) |
D-dimer, median (IQR), n = 105 | 1.7 (0.9, 3.7) |
Alanine aminotransferase, IU/L, median (IQR) | 29 (16, 53) |
Aspartate aminotransferase, IU/L, median (IQR) | 39 (23, 68) |
Alkaline phosphatase, IU/L, median (IQR) | 77 (60, 115) |
Total bilirubin, mean (SD) | 0.4 (0.3) |
Direct bilirubin, mean (SD), n = 92 | 0.2 (0.1) |
Albumin, g/dL, mean (SD) | 3.2 (0.8) |
Prothrombin time, seconds, mean (SD), n = 81 | 16.9 (8.1) |
Table 3 Characteristics of those with and without transaminitis
Transaminitis (n = 73) | No transaminitis (n = 57) | P value | |
Age, yr, median (IQR) | 63 (48, 72) | 62 (48, 76) | 0.9 |
Females | 31 (42.5) | 28 (49.1) | 0.4 |
Body mass index, kg/m2, median (IQR) | 30.2 (26.5, 36.8) | 27.3 (24.5, 33.2) | 0.04 |
Smoking | 19 (26) | 19 (33.3) | 0.4 |
Alcohol | 20 (27.4) | 10 (17.5) | 0.2 |
Diarrhea | 24 (32.9) | 10 (17.5) | 0.05 |
Nausea | 18 (24.7) | 14 (24.6) | 1.0 |
Abdominal pain | 11 (15.1) | 10 (17.5) | 0.7 |
Anorexia | 19 (26) | 15 (26.3) | 1.0 |
Other gastro-intestinal symptoms1 | 19 (26) | 18 (31.6) | 0.5 |
X-ray findings2 | 55 (75.3) | 32 (56.1) | 0.02 |
Hypertension | 38 (52.1) | 31 (54.4) | 0.8 |
Age-adjusted Charlson Index, median (IQR) | 3 (1, 6) | 4 (1, 6) | 0.7 |
On ventilator | 31 (42.5) | 12 (21.1) | 0.01 |
Admitted to intensive care unit | 39 (53.4) | 19 (33.3) | 0.02 |
On medications with GI side-effects | 26 (35.6) | 20 (35.1) | 1.0 |
Alanine aminotransferase, IU/L, median (IQR) | 48 (34, 84) | 15 (10, 20) | < 0.001 |
Aspartate aminotransferase, IU/L, median (IQR) | 66 (42, 100) | 20 (14, 26) | < 0.001 |
Alkaline phosphatase, IU/L, median (IQR) | 97 (66, 124) | 70 (56, 92) | < 0.001 |
Total bilirubin, mean (SD) | 0.6 (0.3) | 0.4 (0.2) | < 0.001 |
Albumin, g/dL, mean (SD) | 3.0 (0.8) | 3.4 (0.7) | 0.01 |
Table 4 Multivariable logistic model for death in patients with and without transaminitis
Variable | Model 1 | Model 2 | Model 3 | |||
OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | |
Transaminitis | 2.9 (1.1-7.4) | 0.03 | 3.1 (1.2-8.0) | 0.02 | 3.4 (1.2-10.1) | 0.03 |
Gender, reference females | - | 0.5 (0.2-1.2) | 0.5 (0.2-1.4) | |||
AACI above median score of 3.5 | - | - | 12.9 (3.5-48.4) | |||
Admission to intensive care unit | - | - | 3.6 (1.2-10.4) |
- Citation: Suresh Kumar VC, Harne PS, Mukherjee S, Gupta K, Masood U, Sharma AV, Lamichhane J, Dhamoon AS, Sapkota B. Transaminitis is an indicator of mortality in patients with COVID-19: A retrospective cohort study. World J Hepatol 2020; 12(9): 619-627
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/619.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.619